TGFB1 and colorectal carcinoma: A handful of clinical trials targeting the CRC CMS4 subtype with novel immunotherapies including anti-PD-1 mAB spartalizumab [85], dual PD-1/TGFB engineered mAB-fusion protein M7824 [86], and a dendritic cell vaccine (AVEVAC) [87] have already begun in the US and EU.